Kurs
-1,82%
Kurs
-1,82%
Open
14,55
High
14,55
Low
13,84
Close
14,05
Kursutveckling under dagen för detta pressmeddelande
(NOK).
Likviditet
14,9 MNOK
Likviditet
14,9 MNOK
Rel. mcap
1,83%
Antal aktier
1 056 604
Likviditet under dagen för detta pressmeddelande
Kalender
| Tid* | ||
| 2025-04-24 | N/A | Årsstämma |
| 2025-02-26 | N/A | Bokslutskommuniké 2024 |
| 2025-01-06 | N/A | Extra Bolagsstämma 2025 |
| 2024-08-30 | - | Kvartalsrapport 2024-Q2 |
| 2024-04-12 | - | X-dag ordinarie utdelning TRMED 0.00 NOK |
| 2024-04-11 | - | Årsstämma |
| 2024-02-28 | - | Bokslutskommuniké 2023 |
| 2023-08-31 | - | Kvartalsrapport 2023-Q2 |
| 2023-04-27 | - | X-dag ordinarie utdelning TRMED 0.00 NOK |
| 2023-04-26 | - | Årsstämma |
| 2023-02-28 | - | Bokslutskommuniké 2022 |
| 2022-08-31 | - | Kvartalsrapport 2022-Q2 |
| 2022-04-29 | - | X-dag ordinarie utdelning TRMED 0.00 NOK |
| 2022-04-28 | - | Årsstämma |
| 2022-03-01 | - | Bokslutskommuniké 2021 |
| 2021-11-18 | - | 15-10 2021-Q3 |
| 2021-08-26 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-26 | - | Kvartalsrapport 2021-Q1 |
| 2021-04-28 | - | Årsstämma |
| 2021-04-16 | - | X-dag ordinarie utdelning TRMED 0.00 NOK |
| 2021-03-22 | - | Extra Bolagsstämma 2021 |
| 2021-02-18 | - | Bokslutskommuniké 2020 |
| 2020-11-19 | - | Kvartalsrapport 2020-Q3 |
| 2020-10-21 | - | Extra Bolagsstämma 2020 |
| 2020-08-27 | - | Kvartalsrapport 2020-Q2 |
| 2020-06-11 | - | X-dag ordinarie utdelning TRMED 0.00 NOK |
| 2020-06-10 | - | Årsstämma |
| 2020-05-26 | - | Kvartalsrapport 2020-Q1 |
| 2020-04-20 | - | X-dag ordinarie utdelning TRMED 0.00 NOK |
| 2020-02-27 | - | Bokslutskommuniké 2019 |
| 2019-11-19 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-22 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-23 | - | Kvartalsrapport 2019-Q1 |
| 2019-04-26 | - | X-dag ordinarie utdelning TRMED 0.00 NOK |
| 2019-04-25 | - | Årsstämma |
| 2019-02-18 | - | Extra Bolagsstämma 2019 |
| 2018-08-22 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-31 | - | X-dag ordinarie utdelning TRMED 0.00 NOK |
| 2018-05-30 | - | Årsstämma |
| 2018-05-30 | - | Kvartalsrapport 2018-Q1 |
| 2018-02-27 | - | Bokslutskommuniké 2017 |
| 2017-12-20 | - | Extra Bolagsstämma 2017 |
| 2017-11-22 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-23 | - | Kvartalsrapport 2017-Q2 |
| 2017-05-26 | - | X-dag ordinarie utdelning TRMED 0.00 NOK |
| 2017-05-24 | - | Årsstämma |
| 2017-05-24 | - | Kvartalsrapport 2017-Q1 |
| 2017-02-28 | - | Bokslutskommuniké 2016 |
| 2016-11-23 | - | Kvartalsrapport 2016-Q3 |
| 2016-10-12 | - | Extra Bolagsstämma 2016 |
| 2016-08-24 | - | Kvartalsrapport 2016-Q2 |
| 2016-05-31 | - | Kapitalmarknadsdag 2016 |
| 2016-05-20 | - | X-dag ordinarie utdelning TRMED 0.00 NOK |
| 2016-05-19 | - | Årsstämma |
| 2016-05-19 | - | Kvartalsrapport 2016-Q1 |
| 2016-02-26 | - | Bokslutskommuniké 2015 |
| 2015-11-17 | - | Kapitalmarknadsdag 2015 |
| 2015-10-21 | - | Kvartalsrapport 2015-Q3 |
| 2015-08-26 | - | Kvartalsrapport 2015-Q2 |
| 2015-05-27 | - | Kvartalsrapport 2015-Q1 |
| 2015-03-09 | - | Årsstämma |
| 2014-11-12 | - | Extra Bolagsstämma 2014 |
Beskrivning
| Land | Norge |
|---|---|
| Lista | OB Match |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
2020-12-07 11:00:14
Oslo, Norway, 7 December 2020<br />
<br />
Nordic Nanovector ASA (OSE: NANOV) announces that its Interim CEO, Dr Lars
Nieba<br />
will present a corporate overview via live webcast at DNB's 11[th] Annual
Nordic<br />
Healthcare Conference, taking place on 15 December 2020.<br />
<br />
Presentations details are as follows:<br />
<br />
DNB's 11[th] Annual Nordic Healthcare Conference<br />
Date: 15 December 2020<br />
Time: 09:50 to 10:10 (CET)<br />
<br />
The presentation will be available at the same time at
www.nordicnanovector.com<br />
in the section: Investors & Media/Reports and Presentation/Presentations.<br />
<br />
For further information, please contact:<br />
<br />
IR enquiries<br />
<br />
Malene Brondberg, CFO<br />
Cell: +44 7561 431 762<br />
Email: ir@nordicnanovector.com<br />
<br />
Media Enquiries<br />
<br />
Mark Swallow/Frazer Hall/David Dible (Citigate Dewe Rogerson)<br />
Tel: +44 203 926 8535<br />
Email: nordicnanovector@citigatedewerogerson.com<br />
<br />
About Nordic Nanovector:<br />
<br />
Nordic Nanovector is committed to develop and deliver innovative therapies to<br
/>
patients to address major unmet medical needs and advance cancer care. The<br />
Company aspires to become a leader in the development of targeted therapies
for<br />
haematological cancers. Nordic Nanovector's lead clinical-stage candidate is<br
/>
Betalutin[®], a novel CD37-targeting radioimmunotherapy designed to advance
the<br />
treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with
substantial<br />
unmet medical need, representing a growing market forecast to be worth nearly<br
/>
USD 29 billion by 2026. Nordic Nanovector retains global marketing rights to<br
/>
Betalutin[®] and intends to actively participate in the commercialisation of<br
/>
Betalutin[®] in the US and other major markets.<br />
<br />
Further information can be found at www.nordicnanovector.com.<br />
<br />
This information is subject to a duty of disclosure pursuant to Sections 4-2
and<br />
5-12 of the Securities Trading Act.